

Oct-13-03 12:57

From-NOVO NORDISK BIOTECH INC

+5307580317

T-584 P.01/07 F-551

**Novozymes Biotech, Inc.
facsimile transmittal**

1445 Drew Avenue

Davis, CA 95616

Fax: 530/758-0317 Tel.: 530/757-8100

RECEIVED
CENTRAL FAX CENTER

OCT 15 2003

To: USPTO

Fax: 703/746-3974

From: Robert L. Starnes

Date: 10/10/2003
13

OFFICIAL

Re: 4990.210-US

Pages: 6

Your 09/712,338

Ref:

☒ **X Urgent**

☐ **For
Review**

☐ **Please
Comment**

☐ **Please
Reply**

☐ **Please
Recycle**

**PLEASE DELIEVER TO EXAMINER
S. SWOPE.**

**Thank you,
Robert L. Starnes**

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

Oct-13-03 12:57

From-NOVO NORDISK BIOTECH INC

+5307580317

T-584 P.02/07 F-551

Confirmation Report-Memory Send

Time : Oct-10-03 10:43
Tel line 1 : +5307580317
Name : NOVO NORDISK BIOTECH INC

Job number : 529
Date : Oct-10 10:41
To : 17037463974
Document Pages : 06
Start time : Oct-10 10:41
End time : Oct-10 10:43
Pages sent : 06

Job number : 529

*** SEND SUCCESSFUL ***

RECEIVED
CENTRAL FAX CENTER

OCT 15 2003

OFFICIAL

Novozymes Biotech, Inc.
Facsimile transmittal
1445 Drew Avenue
Davis, CA 95616
Fax: 530/758-0317 Tel.: 530/757-8100

To:	USPTO	Fax:	703/746-3974
From:	Robert L. Starnes	Date:	10/10/2003
Re:	4990.210-US	Pages:	6
Your Ref:	09/712,338		
<input checked="" type="checkbox"/> Urgent	<input type="checkbox"/> For Review	<input type="checkbox"/> Please Comment	<input type="checkbox"/> Please Reply
			<input type="checkbox"/> Please Recycle

**PLEASE DELIVER TO EXAMINER
S. SWOPE.**

**Thank you,
Robert L. Starnes**

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

Attorney Docket No.: 4990.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky et al.

Confirmation No: 8547

Serial No.: 09/712,338

Group Art Unit: 1633

Filed: November 13, 2000

Examiner: S. Swope

For: Carboxypeptidases and Nucleic Acids Encoding Same

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
P O. Box 1450
Alexandria, VA 22313-1450


Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner S. Swope, fax number (703) 746-3974.

Respectfully submitted,



Seleste Buriani
Novozymes Biotech, Inc.
1445 Drew Avenue
Davis, CA 95616
(530) 757-8100

Date: October 10, 2003

Attorney Docket No. 4990.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Blinkovsky *et al.*

Confirmation No.: 8547

Serial No.: 09/712,338

Group Art Unit: 1633

Filed: November 12, 2000

Examiner: R. Prouty

For: Carboxypeptidases and Nucleic Acids Encoding Same

AMENDMENT

Commissioner for Patents
Washington, DC 20231

In response to a request of Examiner Swope on October 9, 2003, to provide a Compliant Amendment, please amend the above-captioned application as follows:

AMENDMENTS TO THE CLAIMS:

Claim 47 is amended. The following is the status of the claims of the above-captioned application, as amended.

1-29 (Cancelled)

30. (Previously Presented) An isolated nucleic acid sequence encoding a polypeptide having carboxypeptidase activity, selected from the group consisting of:

(a) a nucleic acid sequence encoding a polypeptide having an amino acid sequence which has at least 70% identity with amino acids 19 to 555 of SEQ ID NO. 2;

(b) a nucleic acid sequence having at least 70% homology with nucleotides 55 to 1662 of SEQ ID NO. 1;

(c) a nucleic acid sequence which hybridizes under medium stringency conditions with (i) nucleotides 55 to 1662 of SEQ ID NO. 1, (ii) a subsequence of (i) of at least 100 nucleotides, or (iii) a complementary strand of (i) or (ii), wherein medium stringency conditions